

8/21/2024

Village Farms International (VFF)

Company update: Overweight

| US\$Mn | | | | | | | | |
|--|-----------------------------------|-------|---------------|------------------|--------------|--------|---------|----------------|
| Sales | CY22a | CY23a | CY24e | Prev | CY25e | Prev | CY26e | Prev |
| 1Q | 70.2 | 64.7 | 78.1 A | 78.1 | 78.1 | 80.9 | 82.3 | 86.3 |
| 2Q | 82.9 | 77.2 | 92.2 A | 89.6 | 92.5 | 84.0 | 97.0 | 100.9 |
| 3Q | 71.1 | 69.5 | 82.0 E | 85.5 | 86.1 | 87.5 | 90.9 | 96.6 |
| 4Q | 69.5 | 74.2 | <u>82,1</u> E | 88.6 | 81.9 | 86.7 | 86.2 | <u>99.7</u> |
| FY | 293.6 | 285.6 | 334.4 | 341.8 | 338.6 | 339.1 | 356.3 | 383.5 |
| EBITDA | CY22a | CY23a | CY24e | Prev | CY25e | Prev | CY26e | Prev |
| 1Q | -6.1 | 0.5 | 3.6 A | 3.6 | 5.8 | 8.4 | 7.5 | 8.8 |
| 2Q | -10.3 | 4.5 | -3.6 A | 4.9 | -0.9 | 8.1 | 7.4 | 9.2 |
| 3Q | -2.2 | 3.2 | 3.6 E | 6.7 | 6.8 | 9.4 | 9.6 | 11.5 |
| 4Q. | -2.7 | -0.7 | <u>3.8</u> E | 7.8 | 5.7 | 9.6 | 8.3 | 12.7 |
| FY | -21.3 | 7.6 | 7.4 | 23.0 | 17.3 | 35.5 | 32.8 | 42.2 |
| | | | | | | | | |
| Share pric | e (US\$) | 1.07 | <u>Perf.</u> | VFF | YOLO ETF | 5&P500 | Stance: | Overweight |
| Share cou | nt (mn) | 110.2 | 30d | -1% | -2% | 2% | n | o price target |
| Market Ca | ıp (US\$Mn) | 118 | 90d | -12% | -15% | 5% | | FY=D ec |
| Ticker | | VFF | lyr | 17% | 30% | 27% | | |
| | | | | | | | | |
| Those officer many | land, Inc. (1979-1286) 211720-0-4 | | 442 | 202-6425,229-346 | \$Mn | FY24 | FY25 | FY26 |
| Advantage Notional contenting | | | | | Projected EV | 141 | 132 | 114 |



| \$Mn | FY24 | FY25 | FY26 |
|-----------------|-------|-------|-------|
| Projected EV | 141 | 132 | 114 |
| EV/Sales | 0.4x | 0.4x | 0.3x |
| ev/ebitda | 18.9x | 7.6x | 3.5x |
| | | | |
| | FY24 | FY25 | FY26 |
| Net debt/Sales | x0.0 | x0.0 | na |
| Net debt/EBITDA | -1.4x | -0.1x | na |
| Free Cash Flow | -3.4 | 8.4 | 18.3 |
| Net (debt) cash | -10.2 | -1.9 | 16.4 |
| | | | |
| Consensus | FY24 | FY25 | FY26 |
| Sales | 325.7 | 345.5 | 397.3 |
| EBITDA | 10.8 | 23.3 | 44.2 |
| Guidance CY24: | | n/a | |
| | | | |

Pablo Zuanic

ZUANIC & ASSOCIATES pablo.zuanic@zuanicgroup.com 420Odysseus; www.zuanicassociates.com



Company Update

Outlook

- Regarding the cannabis business, from a strategic point of view, VFF will prioritize the branded domestic cannabis business and international. In this sense, it will sell less into the B2B market for domestic purposes, allocating more output to its suite of domestic brands (value, mainstream, and premium). Recent performance reinforces confidence in the VFF cannabis brand portfolio.
- While the Hifyre scanner data may have overstated VFF's underlying performance for 2Q24 (pointing to >20% qoq growth both for flower and pre-rolls vs. +8% total growth reported), we note in 1Q24 shipments were ahead of scanner trends (reported sales were up 16% in 1Q24 vs. +5% for the scanner trends). What matters is that VFF is growing share.
- As per Hifyre, flower accounted for 79% of VFF cannabis sales in 2Q24 (pre-rolls 20%), with the PSF unit accounting for 62% and Rose Life Sciences (QC) for 38%. Re the PSF flower brand portfolio, the mix in 2Q24 was Original Fraser Valley 40% (average RSP of C\$3.04/gram), Pure Sunfarms 37% (C\$4.92), and Super Toast 18% (C\$4.14). The average flower RPS for the portfolio in 2Q24 was C\$4.38/gram vs. C\$4.24 in 1Q23.
- While international sales remained stable seq in 2Q24 at US\$1.5Mn, VFF is securing new supply contracts overseas (mostly on a B2B model) and projects further growth. Also, part of the company's domestic B2B sales are reshipped overseas by other companies. In the Netherlands, the company controls one of ten licensees that will be allowed to supply coffee shops, which are legally allowed to retail cannabis.
- Still, while domestic and international trends for the cannabis business are encouraging, earnings volatility in the Produce unit continues to impact total EBITDA and cash flow. In our view, this impacts sentiment on the stock and is one of the reasons why VFF trades at a discount despite its low-cost advantage in Canadia cannabis and #2 domestic rec market position. Also, while we value the company's rec franchise, we note this is apparently a mid 20s gross margin business compared with ~60% for companies selling MMJ (medical cannabis) domestically and overseas (see our latest <u>ACB report</u>.
- For greater color on VFF, see our recent Zoom call with management (<u>link</u>) and our deepdive into the latest scanner data trends in domestic rec (<u>report</u>).

Brief 2Q24 highlights. Domestic branded rec sales grew 7% qoq and +34% yoy to C\$41.8Mn (US\$30.5Mn), as PSF continues to gain market share (#2 and closing the gap with #1 Tilray). International sales were stable qoq at US\$1.5Mn, while bulk rose to US\$8.3Mn as the company cleared (bulk-related) inventories and made use of B2B demand (but indicated this number was one-off). Cannabis EBITDA margin rose seq by 90bp to 11.8%. But while the news was positive in the cannabis unit (with EBITDA of \$4.8Mn), total consolidated EBITDA was -\$3.6Mn (vs. +\$3.6Mn in 1Q24) due to a swing in Produce EBITDA to -\$6.4Mn (US CBD -\$0.24Mn; corporate EBITDA was



stable seq at -\$1.85Mn). Total free cash flow for 2Q24 worsened to -\$10Mn vs. -\$1.9Mn in 1Q24. In CY23, a big part of the VFF story was the improvement in FCF to -\$1.2Mn vs. \$34Mn in CY22 and CY23 at -\$61Mn, so the 2Q24 deterioration does raise some concerns. All that said, net debt leverage (-\$19Mn) is only 0.1x sales and 1.3x of EBITDA.

Valuation. At US\$1.07 per share, we calculate an EV of US\$149Mn (111.7mn shares; net debt of \$19Mn; \$10Mn in redeemable non-controlling interest; \$1Mn in leases net of right of use assets). So, taking the spot EV of US\$149Mn, VFF trades at 0.5x FactSet consolidated sales estimates (0.4x on CY25), and 6.6x CY25 EBITDA. If we strip out produce at \$30Mn (5x normalized EBITDA of \$6Mn), US CBD at 1x sales (\$20Mn), and the Texas greenhouses at \$50Mn, that would mean the cannabis business is valued at US\$49Mn, or 0.3x our CY24 sales estimate for the cannabis unit (US\$159.2Mn) and 2.2x EBITDA (\$22.4Mn). We realize questions about the value and upside optionality of the non-cannabis assets are subject to debate, but that should not take away from the thesis of attractive value in VFF. In short, investors can buy the #2 Canadian cannabis producer (one with a sustainable and disciplined financial model, with the lowest production costs, and international optionality) at a rather attractive valuation.




Exhibit 1: Implied Value of Cannabis Strip for Canadian LPs






Table 1: Companies mentioned in this report.

| - | | | |
|---------------------|--------|--------|------------|
| Company name | Ticker | Ticker | Rating |
| US MSOs | | | |
| 4Front Ventures | | FENTE | Not rated |
| Acreage Holdings | | ACRDF | Not rated |
| Ascend Wellness | | AAWH | Not rated |
| AYR Wellness | | AYRWF | Not rated |
| Cannabist | | CCHWF | Not rated |
| Cansortium | | CNTMF | will cover |
| Cresco Labs | | CRLBF | Overweight |
| Curaleaf Holdings | | CURLF | will cover |
| GlassHouse Brands | | GLASF | Not rated |
| Gold Flora | | GRAM | Overweight |
| Goodness Growth | | GDNSF | Not rated |
| Green Thumb Indust | ries | GTBIF | Overweight |
| Grown Rogue | | GRUSF | Not rated |
| Jushi Holdings | | JUSHF | Overweight |
| MariMed | | MRMD | Overweight |
| Planet 13 Holdings | | PLNHF | Overweight |
| Schwazze | | SHWZ | Not rated |
| StateHouse Holdings | Inc | STHZE | Neutral |
| TerrAscend | | TSNDF | Not rated |
| TILT Holdings | | TLLTF | Overweight |
| Trulieve Cannabis | | TCNNF | will cover |
| Verano Holdings | | VRNOF | Overweight |
| Vext Science, Inc. | | VEXTE | will cover |
| Tech | | | |
| Leafly | | LFLY | Not rated |
| Springbig | | SBIG | Not rated |
| WM Technology | | MAPS | Neutral |
| | | | |

| • | - | Bette |
|----------------------------------|--------|------------|
| Company name | Ticker | Rating |
| Canada LPs | | |
| Aurora Cannabis | ACB | Neutral |
| Auxty Cannabis Group | CBWTF | not rated |
| Avant Brands | AVTBF | not rated |
| Avicanna | AVCN | will cover |
| BZAM | BZAMF | not rated |
| Cannara Biotech | LOVFF | not rated |
| Canopy Growth Corporation | CGC | will cover |
| Cronos Group | CRON | not rated |
| Decibel Cannabis Co | DBCCF | Overweight |
| Organigram Holdings | OGI | will cover |
| Rubicon Organics | ROMJF | not rated |
| SNDL | SNDL | not rated |
| Tilray Brands | TLRY | Neutral |
| Village Farms Intl | VFF | Overweight |
| Finance Companies | | |
| AFC Gamma | AFCG | will cover |
| Chicago Atlantic REFC | REFI | Overweight |
| Innovative Industrial Properties | IIPR | will cover |
| New Lake Capital Partners | NLCP | Overweight |
| RIV Capital | CNPOF | not rated |
| SHF Holdings | SHF5 | not rated |
| Silver Spike Inv Corp | SSIC | will cover |
| Other | | |
| Intercure | INCR | Overweight |
| Irwin Naturais | IWINF | Not rated |
| Ispire Technology | ISPR | will cover |
| Smoore International | SMORF | will cover |

Source: Z&A



21 August 2024 Village Farms International: Company Update Post 2Q24 Print

Appendix I: Company Financials



Exhibit 1: Financial Highlights

| US\$Mn | CY22 | CY23 | 1024 | 2Q24 | 3Q24e | 4Q24e | CY24e | 1Q25e | 2Q25e | 3Q25e | 4Q25e | CY25e | CY26e | CY27e |
|-----------------------------|--------|--------|--------|--------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| Proforma consolidated sales | 293.6 | 285.6 | 78.1 | 92.2 | 82.0 | 82.1 | 334.4 | 78.1 | 92.5 | 86.1 | 81.9 | 338.6 | 356.3 | 375.4 |
| qoq ch % | na | na | 5% | 18% | -11% | 0% | na | -5% | 18% | -7% | -5% | na | na | na |
| yoy ch % | 10% | -3% | 21% | 19% | 18% | 11% | 17% | 0% | 0% | 5% | 0% | 1% | 5% | 5% |
| guidance | | na | | | | | na | | | | | na | na | na |
| consensus | | | | | 80.6 | 81.5 | 325.7 | 80.7 | 92.4 | 88.2 | 89.1 | 345.5 | 397.3 | na |
| Profit margins | | | | | | | | | | | | | | |
| Gross profit after FV adj | 27.5 | 49.4 | 15.5 | 9.2 | 14.9 | 15.2 | 54.9 | 16.9 | 11.3 | 18.2 | 17.0 | 63.5 | 81.3 | 87.5 |
| as % of sales | 9.4% | 17.3% | 19.9% | 10.0% | 18.2% | 18.5% | 16.4% | 21.6% | 12.3% | 21.2% | 20.8% | 18.7% | 22.8% | 23.3% |
| Ор екр | 72.3 | 65.5 | 16.4 | 19.7 | 16.2 | 16.3 | 68.5 | 16.0 | 17.2 | 16.3 | 16.3 | 65.8 | 68.3 | 71.0 |
| as % of sales | 24.6% | 22.9% | 21.0% | 21.3% | 19.7% | 19.8% | 20.5% | 20.5% | 18.6% | 19.0% | 19.9% | 19.4% | 19.2% | 18.9% |
| EBIT | -44.8 | -16.1 | -0.9 | -10.4 | -1.2 | -1.1 | -13.6 | 0.9 | -5.8 | 1.9 | 0.7 | -2.3 | 12.9 | 16.6 |
| as % of sales | -15.2% | -5.6% | -1.1% | -11.3% | -1.5% | -1.3% | -4.1% | 1.2% | -6.3% | 2.2% | 0.9% | -0.7% | 3.6% | 4.4% |
| Adj EBITDA | -21.3 | 7.6 | 3.6 | -3.6 | 3.6 | 3.8 | 7.4 | 5.8 | -0.9 | 6.8 | 5.7 | 17.3 | 32.8 | 36.8 |
| as % of sales | -7.3% | 2.7% | 4.6% | -3.9% | 4.4% | 4.6% | 2.2% | 7.4% | -1.0% | 7.9% | 6.9% | 5.1% | 9.2% | 9.8% |
| consensus | | | | | 3.6 | 4.2 | 10.8 | 5.5 | 5.0 | 6.6 | 6.8 | 23.3 | 44.2 | na |
| as % of sales | | | | | 4.4% | 5.2% | 3.3% | 6.8% | 5.4% | 7.5% | 7.7% | 6.7% | 11.1% | na |
| EPS | | | | | | | | | | | | | | |
| Pre tax income | -96.7 | -27.4 | -2.4 | -23.3 | -2.0 | -1.7 | -29.3 | 0.3 | -6.5 | 1.2 | 0.1 | -4.9 | 10.7 | 14.9 |
| Tax rate assumption | -4.8% | -16.3% | -13.6% | -1.1% | 20.0% | 20.0% | 0.5% | 20.0% | 20.0% | 20.0% | 20.0% | 20.0% | 20.0% | 20.0% |
| Net income | -101.4 | -31.8 | -2.7 | -23.6 | -1.6 | -1.4 | -29.2 | 0.2 | -5.2 | 1.0 | 0.1 | -3.9 | 8.6 | 11.9 |
| Share count (FD) Mn | 89.1 | 108.7 | 110.2 | 111.0 | 111.0 | 111.0 | 110.8 | 111.0 | 111.0 | 111.0 | 111.0 | 111.0 | 111.0 | 111.0 |
| EPS | -1.13 | -0.29 | -0.03 | -0.21 | -0.01 | -0.01 | -0.26 | 0.00 | -0.05 | 0.01 | 0.00 | -0.04 | 80.0 | 0.11 |
| consensus | | | | | -0.02 | -0.02 | -0.19 | 0.00 | -0.01 | 0.01 | 0.01 | 0.02 | 0.21 | na |
| BS & CF highlights | | | | | | | | | | | | | | |
| Operating cash flow | -19.9 | 5.3 | -0.1 | -7.0 | 8.7 | 3.4 | 5.1 | 7.2 | -7.9 | 9.3 | 7.2 | 15.8 | 26.2 | 33.5 |
| (-) Capex | -14.3 | -6.5 | -1.9 | -3.0 | -1.8 | -1.8 | -8.5 | -1.7 | -2.0 | -1.9 | -1.8 | -7.4 | -7.8 | -8.3 |
| Free cash flow | -34.2 | -1.2 | -1.9 | -10.0 | 6.9 | 1.6 | -3.4 | 5.5 | -10.0 | 7.4 | 5.4 | 8.4 | 18.3 | 25.3 |
| Ending net cash (debt) | -39.3 | -16.8 | -18.4 | -18.8 | -11.8 | -10.2 | -10.2 | -4.7 | -14.7 | -7.3 | -1.9 | -1.9 | 16.4 | 41.7 |
| Net debt/Sales | -0.1x | -0.1x | -0.1x | -0.1x | x0.0 | 0.0x | 0.0x | 0.0x | 0.0x | 0.0x | x0.0 | 0.0x | 0.0x | 0.1x |
| Net debt/EBITDA | 1.8x | -2.2x | -1.3x | 1.3x | -0.8x | -0.7x | -1.4x | -0.2x | 3.9x | -0.3x | -0.1x | -0.1x | 0.5x | 1.1x |
| Equity | 303.1 | 302.6 | 296.2 | 275.2 | 273.6 | 272.2 | 272.2 | 272.4 | 267.2 | 268.2 | 268.3 | 268.3 | 276.9 | 288.8 |



Exhibit 2: Divisional Split

| US\$Mn | CY22 | CY23 | 1Q24 | 2Q24 | 3Q24e | 4Q24e | CY24e | 1Q25e | 2Q25e | 3Q25e | 4Q25e | CY25e | CY26e | CY27e |
|-----------------|--------|-------|--------|--------|-------|-------|-------|-------|--------|-------|-------|-------|-------|-------|
| Sales | 293.6 | 285.6 | 78.1 | 92.2 | 82.0 | 82.1 | 334.4 | 78.1 | 92.5 | 86.1 | 81.9 | 338.6 | 356.3 | 375.4 |
| Produce | 160.3 | 151.2 | 36.1 | 47.0 | 37.1 | 38.6 | 158.9 | 36.5 | 47.5 | 37.5 | 39.0 | 160,4 | 162.0 | 163.7 |
| Cannabis | 109.9 | 114.0 | 37,4 | 40.7 | 40.5 | 39.2 | 157.9 | 37.3 | 40.6 | 44.2 | 38.5 | 160.5 | 176.3 | 193,4 |
| Energy | 0.1 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| US CBD | 23.3 | 20.3 | 4.5 | 4.3 | 4.3 | 4.3 | 17.5 | 4.4 | 4.4 | 4.4 | 4.4 | 17.6 | 17.9 | 18.3 |
| Gross Margin | 9.4% | 17.3% | 19.9% | 10.0% | 18.2% | 18.5% | 16.4% | 21.6% | 12.3% | 21,2% | 20.8% | 18.7% | 22.8% | 23.3% |
| Produce | -10.8% | 0.1% | 9.2% | -8.9% | 3.0% | 4.0% | 1.1% | 9.3% | -8.8% | 3.1% | 4.1% | 1.2% | 5.4% | 5.4% |
| Cannabis | 26.7% | 31.5% | 25.4% | 26.3% | 28.0% | 30.0% | 27.4% | 31.0% | 32.0% | 33.0% | 35.0% | 32.8% | 35.0% | 35.0% |
| Energy | na | na | na | na | na | na | na | na | na | na | na | na | na | na |
| US CBD | 67.2% | 65.6% | 59.4% | 61.2% | 60.0% | 60.0% | 60.1% | 60.0% | 60.0% | 60.0% | 60.0% | 60.0% | 60.0% | 60.0% |
| EBITDA | -21.3 | 7.6 | 3.6 | -3.6 | 3.6 | 3.8 | 7.4 | 5.8 | -0.9 | 6.8 | 5.7 | 17.3 | 32.8 | 36.8 |
| Produce | -24.4 | 0.5 | 2.0 | -6.4 | 0.7 | 1.1 | -2.5 | 3.0 | -5.2 | 8.0 | 1.1 | -0.3 | 6.5 | 6.6 |
| Cannabis | 13.1 | 14.8 | 4.1 | 4.8 | 6.4 | 6.8 | 22.0 | 6.6 | 0.8 | 9.6 | 8.5 | 32.7 | 40.1 | 44.3 |
| Energy | -0.3 | -0.2 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -0.1 | -0.1 | -0.1 |
| US CBD | 0.2 | 0.9 | -0.6 | -0.2 | -0.4 | -0.4 | -1.6 | -0.4 | -0.3 | -0.3 | -0.3 | -1.4 | -1.1 | -0.9 |
| Corporate | -10.0 | -8.4 | -1.9 | -1.8 | -3.1 | -3.6 | -10.4 | -3.5 | -3.4 | -3.2 | -3.6 | -13.7 | -12.5 | -13.1 |
| EBITDA margin | -7.3% | 2.7% | 4.6% | -3.9% | 4.4% | 4.6% | 2.2% | 7.4% | -1.0% | 7.9% | 6.9% | 5.1% | 9.2% | 9.8% |
| Produce | -15.2% | 0.3% | 5.6% | -13.5% | 1.9% | 2.7% | -1.6% | 8.3% | -10.9% | 2.0% | 2.9% | -0.2% | 4.0% | 4.1% |
| Cannabis | 11.9% | 12.9% | 10.9% | 11.8% | 15.7% | 17.3% | 13.9% | 17.6% | 19.7% | 21.7% | 22.1% | 20.4% | 22.7% | 22.9% |
| Energy | na | na | na | na | na | na | na | na | na | na | na | na | na | na |
| US CBD | 1.0% | 4.2% | -13.6% | -5.6% | -8.9% | -8.6% | -9.2% | -8.2% | -7.9% | -7.5% | -7.2% | -7.7% | -6.3% | -5.0% |
| Corp as % of to | -3,4% | -2.9% | -2.4% | -2.0% | -3.7% | -4.4% | -3.1% | -4.4% | -3.7% | -3.7% | -4,4% | -4.0% | -3.5% | -3.5% |



Exhibit 3: Cannabis Projections

| US\$Mn | CY22 | CY23 | 1Q24 | 2Q24 | 3Q24e | 4Q24e | CY24e | 1Q25e | 2Q25e | 3Q25e | 4Q25e | CY25e | CY26e | CY2 |
|--------------------|-------|-----------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-----|
| Sales | 107.2 | 112.0 | 37.0 | 40.3 | 40.5 | 39.2 | 157.0 | 37.3 | 40.6 | 44,2 | 38.5 | 160.5 | 176.3 | 19 |
| Canada cannab | 103.4 | 107.4 | 35.5 | 38.8 | 39.0 | 37.5 | 150.8 | 35.6 | 38.8 | 42.2 | 36.5 | 153.0 | 167.2 | 18 |
| branded | 85.5 | 91.9 | 29.0 | 30.5 | 32.5 | 31.7 | 123.7 | 30.1 | 32.8 | 35.8 | 31.0 | 129.7 | 142.7 | 15 |
| bulk | 17.8 | 15.5 | 6.5 | 8.3 | 6.5 | 5.9 | 27.1 | 5.5 | 5.9 | 6.4 | 5.5 | 23.3 | 24.5 | 2 |
| International | 3.9 | 4.6 | 1.5 | 1.5 | 1.6 | 1.7 | 6.2 | 1.7 | 1.8 | 1.9 | 2.0 | 7.5 | 9.1 | 1 |
| Cannabis P&L | | | | | | | | | | | | | | |
| Sales | 107.2 | 112.0 | 37.0 | 40.3 | 40.5 | 39.2 | 157.0 | 37.3 | 40.6 | 44.2 | 38.5 | 160.5 | 176.3 | 19 |
| qoq ch % | na | na | 17% | 9% | 1% | -3% | na | -5% | 9% | 9% | -13% | na | na | |
| yoy ch % | 11% | 4% | 47% | 44% | 44% | 24% | 40% | 1% | 1% | 9% | -2% | 2% | 10% | |
| Gross profit | 29.4 | 35.9 | 9.5 | 10.7 | 11.3 | 11.8 | 43.3 | 11.6 | 13.0 | 14.6 | 13.5 | 52.6 | 61.7 | (|
| as % of sales | 27.4% | 32.1% | 25.7% | 26.6% | 28.0% | 30.0% | 27.6% | 31.0% | 32.0% | 33.0% | 35.0% | 32.8% | 35.0% | 35 |
| EBIT | -2.2 | 4.5 | 2.1 | 1.7 | 3.8 | 4.3 | 11.8 | 4.1 | 5.5 | 7.1 | 6.0 | 22.6 | 29.8 | 5 |
| as % of sales | -2.1% | 4.0% | 5.6% | 4.2% | 9.5% | 10.9% | 7.5% | 10.9% | 13.5% | 16.0% | 15.5% | 14.1% | 16.9% | 17 |
| EBITDA | 13.1 | 14.8 | 4.1 | 4.8 | 6.4 | 6.8 | 22.0 | 6.6 | 8.0 | 9.6 | 8.5 | 32.7 | 40.1 | 4 |
| as % of sales | 12.2% | 13.2% | 11.0% | 12.0% | 15.7% | 17.3% | 14.0% | 17.6% | 19.7% | 21.7% | 22.1% | 20.4% | 22.7% | 22 |
| Branded rec assump | tions | | | | | | | | | | | | | |
| Canada rec mar | 4,518 | 5,163 | 1,196 | 1,289 | 1,391 | 1,338 | 5,214 | 1,255 | 1,354 | 1,460 | 1,249 | 5,318 | 5,584 | 5,1 |
| Canada rec mar | 3,470 | 3,826 | 887 | 942 | 1,014 | 977 | 3,821 | 917 | 989 | 1,067 | 912 | 3,884 | 4,078 | 4, |
| wholesale adj | 1,388 | 1,531 | 355 | 377 | 406 | 391 | 1,528 | 367 | 395 | 427 | 365 | 1,554 | 1,631 | 1, |
| PSF branded sa | 85.5 | , 91.9 | 29.0 | 30.5 | 32.5 | 31.7 | 123.7 | 30.1 | 32.8 | 35.8 | 31.0 | 129.7 | 142.7 | 1 |
| in C\$Mn | 112.2 | 124.0 | 39.1 | 41.8 | 44.5 | 43.4 | 168.7 | 41.2 | 44.9 | 49.1 | 42.5 | 177.7 | 195.5 | 2 |
| share % | 6.2% | 6.0% | 8.2% | 8.1% | 8.0% | 8.1% | 8.1% | 8.2% | 8.3% | 8.4% | 8.5% | 8.4% | 8.8% | ę |

Source: Z&A estimates, Hifyre, StatCan, company reports



Exhibit 4: Canadian Cannabis Rec Market Assumptions

| Mn | 2019 | 2020 | 2021 | 2022 | 2023 | 1Q24e | 2Q24e | 3Q24e | 4Q24e | 2024e | 2025e | 2026e | 2027e | 2028 |
|-------------------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| | | | | | | ż | | ÷ | ÷ | | | | | |
| Our projections | | | | | | | | | | | | | | |
| Rec (US\$) | 926 | 1,955 | 3,092 | 3,470 | 3,826 | 887 | 942 | 1,014 | 977 | 3,821 | 3,884 | 4,078 | 4,282 | 4,496 |
| Rec (C\$) | 1,188 | 2,620 | 3,875 | 4,518 | 5,163 | 1,196 | 1,289 | 1,391 | 1,338 | 5,214 | 5,318 | 5,584 | 5,864 | 6,157 |
| yoy ch % | 679% | 121% | 48% | 17% | 14% | 1% | 1% | 1% | 1% | 1% | 2% | 5% | 5% | 5% |
| qoq ch % | na | na | na | na | na | -10% | 8% | 8% | -4% | na | na | na | na | na |
| | | | | | | | | | | | | | | |
| | Nov | Nov | Nov | Nov | Nov | Feb | May | Aug | Nov | Nov | Nov | Nov | Nov | Nov |
| Rec (C\$) | 1,097 | 2,470 | 3,819 | 4,448 | 5,140 | 1,237 | 1,258 | 1,357 | 1,356 | 5,209 | 5,348 | 5,564 | 5,917 | 6,220 |
| yoy ch % | | 125% | 55% | 16% | 16% | 4% | 0% | 0% | 2% | 1% | 3% | 4% | 6% | 5% |
| qoq ch % | na | na | na | na | na | -7% | 2% | 8% | 0% | na | na | na | na | na |
| | | | | | | | | | | | | | | |
| Sales by province | 1,188 | 2,620 | 3,875 | 4,518 | 5,163 | 1,196 | 1,289 | 1,391 | 1,338 | 5,214 | 5,318 | 5,584 | 5,864 | 6,157 |
| Ontario | 254 | 722 | 1,423 | 1,803 | 2,125 | 457 | | | | | | | | |
| Alberta | 286 | 575 | 717 | 797 | 894 | 223 | | | | | | | | |
| British Columbia | 255 | 370 | 551 | 670 | 797 | 175 | | | | | | | | |
| Quebec | 97 | 496 | 601 | 586 | 623 | 160 | | | | | | | | |
| Rest | 296 | 457 | 583 | 662 | 723 | 180 | | | | | | | | |
| YoY ch % | | 121% | 48% | 17% | 14% | 1% | | | | | | | | |
| Ontario | | 184% | 97% | 27% | 18% | -6% | | | | | | | | |
| Alberta | | 101% | 25% | 11% | 12% | 8% | | | | | | | | |
| British Columbia | | 45% | 49% | 21% | 19% | -3% | | | | | | | | |
| Quebec | | 412% | 21% | -2% | 6% | 10% | | | | | | | | |
| Rest | | 54% | 28% | 14% | 9% | 10% | | | | | | | | |
| QoQ ch % | | na | na | na | na | -10% | | | | | | | | |



Exhibit 5: Cash Flow

| IS\$ 000s | | | | | | | | | | | | | | |
|--------------------------------|----------|---------|---------|---------|---------|---------|---------|--------|---------|--------|--------|--------|--------|--------|
| UMMARY CASH FLOW | CY22 | CY23 | 1Q24 | 2Q24 | 3Q24e | 4Q24e | CY24e | 1Q25e | 2Q25e | 3Q25e | 4Q25e | CY25e | CY26e | CY27e |
| | | | | | | | | | | | | | | |
| Net earnings | -101,146 | -31,798 | -2,852 | -23,549 | -1,563 | -1,385 | -29,349 | 212 | -5,188 | 989 | 87 | -3,900 | 8,552 | 11,920 |
| (+) D&A | 13,054 | 15,926 | 4,558 | 4,840 | 4,847 | 4,868 | 19,113 | 4,868 | 4,889 | 4,913 | 4,936 | 19,606 | 19,881 | 20,267 |
| Cash earnings | -88,092 | -15,872 | 1,706 | -18,709 | 3,283 | 3,483 | -10,236 | 5,080 | -300 | 5,902 | 5,023 | 15,706 | 28,434 | 32,187 |
| (-) Working capital changes | -2,246 | -2,088 | -3,290 | -3,109 | 5,434 | -75 | -1,040 | 2,135 | -7,640 | 3,404 | 2,218 | 117 | -2,277 | 1,356 |
| (-) Other operating flows | 70,449 | 23,275 | 1,534 | 14,799 | 1 | 1 | 16,334 | 1 | 0 | 0 | 0 | 2 | 2 | 1 |
| Net operating cash flow | -19,889 | 5,315 | -50 | -7,019 | 8,718 | 3,409 | 5,058 | 7,215 | -7,939 | 9,307 | 7,242 | 15,825 | 26,158 | 33,544 |
| (-) net capex | -14,292 | -6,518 | -1,876 | -3,003 | -1,804 | -1,807 | -8,490 | -1,719 | -2,034 | -1,894 | -1,802 | -7,449 | -7,839 | -8,258 |
| Free cash flow | -34,181 | -1,203 | -1,926 | -10,022 | 6,914 | 1,602 | -3,432 | 5,496 | -9,973 | 7,413 | 5,440 | 8,376 | 18,319 | 25,287 |
| (-) acquisitions | -5,873 | 0 | 0 | -3,096 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | C |
| (-) divestitures | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| (+) other | 4,778 | -1,099 | 295 | 12,754 | 0 | 0 | 13,049 | 0 | 0 | 0 | 0 | 0 | O | 0 |
| (+) share issuance/repurchases | 6,692 | 24,772 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| (-) stock options/warrants | 192 | 83 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | C |
| Change in net | -28,392 | 22,553 | -1,631 | -364 | 6,914 | 1,602 | 6,521 | 5,496 | -9,973 | 7,413 | 5,440 | 8,376 | 18,319 | 25,287 |
| | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Ending net (debt) | -39,320 | -16,767 | -18,398 | -18,762 | -11,848 | -10,246 | -10,246 | -4,749 | -14,722 | -7,309 | -1,869 | -1,869 | 16,450 | 41,736 |
| Cash/inv/sec | 21,676 | 35,291 | 31,685 | 29,657 | 34,612 | 36,227 | 36,227 | 41,346 | 32,722 | 39,534 | 44,583 | 44,583 | 63,304 | 88,351 |
| Gross debts/loans/bonds | 60,996 | 52,058 | 50,083 | 48,419 | 46,459 | 46,472 | 46,472 | 46,095 | 47,445 | 46,844 | 46,452 | 46,452 | 46,854 | 46,614 |
| Net debt / Sales | -0.1x | -0.1x | -0.1× | -0.1x | 0.0x | 0.0x | 0.0x | 0.0x | 0.0× | 0.0x | 0.0x | 0.0ж | 0.0x | 0.1x |
| Net debt / Adj EBITDA | 1.1x | -2.2x | -1.3х | 1.3x | -0.8x | -0.7x | -1.4x | -0.2x | 3.9x | -0.3x | -0.1x | -0.1x | 0.5x | 1.1x |



21 August 2024 Village Farms International: Company Update Post 2Q24 Print

Appendix II: Valuation Comps



Exhibit 6: Canada LPs - Valuation Multiples (consolidated multiples)

| | | | | | | | | <u>Financia</u> | Net Debt | | B | roadly Def | ined Net Deb | t |
|-----------------------------------|----------------|-------------|------|------------------|--------------|--------|---------|-----------------|----------|-------|---------|------------|--------------|--------|
| Multiples | <u>Z&A</u> | Spot EV / S | ales | <u>Z&A S</u> | ipot EV / El | BITDA | Sa | es | EBIT | DA | Sal | <u>es</u> | EBIT | DA |
| 21-Aug-24 | Current | 2024 | 2025 | Current | 2024 | 2025 | Current | CY24 | Current | CY24 | Current | CY24 | Current | CY24 |
| | | | | | | | | | | | | | | |
| Aurora Cannabis Inc. | 1.9x | 1.6x | 1.5x | 54.1x | 23.1x | 14.6x | na | na | na | na | 0.0x | na | 1.4x | na |
| Auxly Cannabis Group Inc. | 1.2x | na | na | 13.9x | na | na | -0.4x | na | -5.0x | na | -0.6x | na | -6.8x | na |
| Avant Brands Inc | 0.9x | na | na | 2.0x | na | na | -0.2x | na | -0.4x | na | -0.5x | na | -1,1x | na |
| BZAM Ltd | 0.6x | na | na | -1.5x | na | na | -0.4x | na | 1.0x | na | -0.5x | na | 1.4x | na |
| Cannara Biotech | 1.4x | na | na | 8.0x | na | na | -0.6x | na | -3.3x | na | -0.6x | na | -3.3x | na |
| Canopy Growth Corporation | 1.1x | 4.7x | 2.9x | -5.7x | -77.4x | 156.5x | -0.3x | -1.3x | 1.6x | 21.0x | -0.3x | -1.3x | 1.6x | 21.0x |
| Cronos Group Inc | 0.7x | 0.6x | 0.5x | -1.6x | -1.9x | -57.9x | na | na | na | na | 8.4x | 7.7x | -20.0x | -24.5x |
| Decibel Cannabis Company Inc | 0.9x | 0.8x | 0.7x | 5.0x | 4.2x | 3.2x | -0.4x | -0.4x | -2.6x | -2.2x | -0.4x | -0.4x | -2.6x | -2.2x |
| High Tide, Inc. | 0.4x | 0.4x | 0.4x | 5.2x | 5.5x | 4.3x | 0.0x | 0.0x | 0.0x | 0.0x | 0.0x | 0.0x | -0.1x | -0.1x |
| Nova Cannabis Inc | 0.4x | 0.4x | 0.3x | 6.1x | 5.5x | 3.7x | 0.0x | 0.0x | 0.0x | 0.0x | 0.0x | 0.0x | -0.5x | -0.4x |
| OrganiGram Holdings Inc | 1.3x | 1.2x | 1.0x | -13.1x | 39.7x | 13.6x | na | na | na | na | 0.5x | 0.5x | -5.0x | 15.2x |
| Rubicon Organics, Inc. | 0.9x | na | na | -18.3x | na | na | -0.1x | na | 1.7x | na | -0.1x | na | 1.7x | na |
| SNDL Inc. | 0.8x | 0.7x | 0.6x | 15.2x | 73.6x | na | na | na | na | na | 0.2x | 0.2x | 4.3x | 20.9x |
| Tilray Brands, Inc. | 2.3x | 1.9x | 1.7x | 42.0x | 18.5x | 14.5x | -0.1x | -0.1x | -1.5x | -0.7x | -0.2x | -0.1x | -3,1x | -1.4x |
| Village Farms International, Inc. | 0.5x | 0.5x | 0.4x | 10.4x | 17.1x | 6.3x | -0, 1x | -0.1x | -1.3x | -2.1x | -0.1x | -0.1x | -1.4x | -2,2x |

Source: FactSet and company reports



Exhibit 7: Canada LPs - EV Calculations

| C\$Mn 21-Aug-24 | FactSet Spot EV | Z&A Spot EV | C\$ price | mn shares | mn deriv | Total Mkt Cap | Financial net debt | Net leases | ST income tax liab. | Conting Cons. | ITM deriv inflow | Total BDND | Pref Stock Min Int |
|-----------------------------------|--------------------|----------------|--------------|--------------|-------------|------------------|-----------------------|---------------|------------------------|------------------|---------------------|---------------|-----------------------|
| | Sporev | Sporev | price | Shares | ucity | wike cup | The to de bit | icuses | | 001131 | | UDITD | |
| Aurora Cannabis Inc. | 411 | 502 | 8.68 | 54.6 | 0.0 | 474 | 63 | -50 | | 0 | | 13 | 41 |
| Auxly Cannabis Group Inc. | 173 | 125 | 0.04 | 1,250.3 | 249.9 | 64 | -45 | -16 | | 0 | | -61 | |
| Avant Brands Inc | 20 | 30 | 0.05 | 278.6 | 2.0 | 14 | -6 | -10 | | | | -16 | |
| BZAM Ltd | 116 | 49 | 0.02 | 180.8 | 0.2 | 4 | -31 | -14 | | | | -45 | |
| Cannara Biotech | 85 | 112 | 0.73 | 90.0 | 0.0 | 65 | -46 | 0 | -1 | | | -46 | |
| Canopy Growth Corporation | na | 1,351 | 8.72 | 111.1 | 1.8 | 985 | -366 | | | | | -366 | |
| Cronos Group Inc | 85 | 91 | 3.23 | 382.0 | 7.8 | 1,260 | 1,171 | -2 | | | | 1,169 | |
| Decibel Cannabis Company Inc | 71 | 71 | 0.08 | 409.0 | 15.8 | 34 | -38 | 1 | | | | -37 | |
| High Tide, Inc. | 219 | 215 | 2.68 | 78.6 | 0.4 | 212 | 0 | -3 | | | | -3 | |
| Nova Cannabis Inc | 1 | 109 | 1.75 | 57.3 | | 100 | -1 | -8 | | | | -9 | |
| OrganiGram Holdings Inc | 189 | 189 | 2.63 | 94.5 | 5.0 | 262 | 72 | | 0 | | | 72 | |
| Rubicon Organics, Inc. | 32 | 31 | 0.47 | 56.2 | 4.1 | 28 | -3 | 0 | | | | -3 | |
| SNDL Inc. | 511 | 622 | 2.92 | 263.2 | 10.9 | 799 | 217 | -40 | | | | 177 | |
| Tilray Brands, Inc. | 2,245 | 2,337 | 2.56 | 831.9 | | 2,130 | -84 | -68 | | -21 | | -172 | 34 |
| Village Farms International, Inc. | 184 | 205 | 1.47 | 111.7 | | 164 | -26 | -1 | | | | -27 | 15 |
| | | | | | | | | | | | | | |

Source: FactSet and company reports




Exhibit 8: Canada LPs - Implied Value of Cannabis Strip

| CŞMn | Aurora | Auxly | Avant | BZAM | Cannara | Canopy | Cronos | Decibel | OGI | Rubicon | SNDL | Tilray | VFF |
|-----------------|--------|-------|-------|------|---------|--------|--------|---------|------|---------|-------|--------|------|
| Total EV | 502 | 125 | 30 | 49 | 112 | 1,351 | 91 | 71 | 189 | 31 | 622 | 2,337 | 205 |
| MJ EV | 457 | 125 | 30 | 49 | 112 | 701 | 91 | 71 | 189 | 31 | -238 | 1,413 | 68 |
| MJ Sales (ann.) | 227 | 108 | 19 | 88 | 79 | 203 | 127 | 111 | 158 | 40 | 77 | 369 | 174 |
| MJ multiple | 2.0x | 1.2x | 1.5x | 0.6x | 1.4x | 3.5x | 0.7x | 0.6x | 1.2x | 0.8x | -3.1x | 3.8x | 0.4x |

Note: We take acquisition value in the case of CGC's units (Storz & Bickel, Wana, Jetty) and market value for stakes in Acreage/TerrAscend Source: FactSet; Z&A Estimates

Exhibit 9: Implied Value of Cannabis Strip for Canada LPs



Source: FactSet; Z&A Estimates



Last

12mo

27%

-74%

-86%

175%

54%

32%

-47%

-34%

51%

-32%

218%

29%

-2%

30%

-25%

17%

-30%

-100%

24%

na

63%

-71%

-62%

-9%

Exhibit 10: Stock Performance

| ug-24 | Sto | ck Performa | nce | | | |
|---------|--------|-------------|------|---------------|--------------------------|--|
| | Last | Last | Last | | Last | |
| Ticker | 30d | 90d | 12mo | Ticker | 30d | |
| US MSOs | | | | Canadian LP | s | |
| AAWH | 21% | -8% | 99% | ACB | 10% | |
| ACRDF | -31% | -52% | -3% | AVTBF | -18% | |
| AYRWF | -11% | -27% | 123% | BZAMF | -41% | |
| CBSTF | 31% | 0% | -35% | CBWTF | 27% | |
| CNTMF | -4% | -18% | 120% | CGC | -11% | |
| CRLBF | 8% | -13% | 67% | CRON | -1% | |
| CURLF | -25% | -39% | 7% | DBCCF | 53% | |
| CXXIF | 0% | -30% | -5% | ETRGF | 23% | |
| FENTE | -45% | -42% | -39% | НП | 5% | |
| GLASE | 40% | 4% | 149% | LOVFF | 21% | |
| GRAMF | -39% | -61% | -32% | NVACE | 45% | |
| GDNSF | 6% | -21% | 370% | OGI | 16% | |
| GRUSF | 3% | -27% | 236% | ROMJE | 0% | |
| GTBIF | -5% | -14% | 56% | SNDL | 3% | |
| ITHUF | -13% | -23% | 12% | TLRY | 4% | |
| JUSHF | 4% | -15% | 33% | VFF | -1% | |
| LOWLF | -65% | -85% | -96% | Cannabis - Ir | Cannabis - International | |
| MRMD | 16% | -19% | -34% | CLVR | -99% | |
| PLNH | 27% | 2% | 21% | IMCC | 29% | |
| SHWZ | -40% | -65% | -75% | INCR | -16% | |
| STHZF | 22900% | 53% | -1% | LGPPF | na | |
| TCNNF | -4% | -14% | 162% | PCLOF | -14% | |
| TLTFF | -15% | -48% | -38% | Tech | | |
| TSNDF | 16% | -9% | -17% | LFLY | -9% | |
| VEXTE | -4% | -20% | -1% | SBIG | -42% | |
| VRNOF | 3% | -17% | 43% | MAPS | 3% | |

| | _ | ck Performar | _ |
|--------------|------|--------------|------|
| | Last | Last | Last |
| Ticker | 30d | 90d | 12mo |
| MJ Fincos | | | |
| AFCG | 7% | -19% | -19% |
| CNPOF | 28% | 13% | 24% |
| IIPR | 1% | 8% | 56% |
| NLCP | 2% | -4% | 57% |
| PW | 16% | 100% | 23% |
| SHF5 | 0% | -17% | 50% |
| 55IC | -4% | 1% | 21% |
| REFI | -3% | 0% | 9% |
| Pix & Shovel | | | |
| AGFY | -23% | -24% | -89% |
| GRWG | -8% | -12% | -20% |
| HYFM | -16% | -32% | -47% |
| SMG | 7% | 8% | 44% |
| UGRO | -1% | -9% | 32% |
| Vape parts | | | |
| GNLN | 182% | 40% | -1% |
| ISP R | 16% | -2% | -24% |
| SMORF | -18% | 6% | 2% |
| TLLTF | -15% | -48% | -38% |
| Index | | | |
| S&P 500 | 2% | 5% | 27% |
| S&P 477 | 4% | 5% | 14% |
| Nasdaq | 12% | 12% | 35% |
| MSOS ETF | -4% | -20% | 42% |
| YOLO ETF | -2% | -15% | 30% |

Source: FactSet



21 August 2024 Village Farms International: Company Update Post 2Q24 Print

Appendix III: Bio and Disclaimers



Analyst Bio

Pablo Zuanic is a well-known and highly rated equity analyst following the cannabis and psychedelics sector. Over the past five years he launched coverage of over 40 companies in the US, Canada, and overseas (MSOs, LPs, CBD, ancillary, psychedelics), kept close track of sectoral trends, and followed the reform process in the US, Canada, Germany, Australia, and elsewhere. His firm Zuanic & Associates publishes equity research on the cannabis and psychedelics sectors, both from a macro/sectoral level in a thematic manner, as well as on listed stocks. The research service is aimed at institutional investors and corporations. The firm is also available for short-term consulting and research advisory projects. Now, more than a year since its inception, the firm has collaborated with over 25 companies (in North America and overseas; plant touching and service providers; public and private), both on an on-going basis as well for specific projects. At various points in his career, Pablo Zuanic was II ranked and called as expert witness in industry investigations. He has a deep global background having covered stocks over the past 20 years in the US, Europe, Latin America, and Asia, across consumer sub sectors. Prior employers include JP Morgan, Barings, and Cantor Fitzgerald. An MBA graduate of Harvard Business School, he started his career as a management consultant, which brings a strategic mindset to his approach to equity research. *Pablo Zuanic can be contacted via the company's portal <u>www.zuanicassociates.com</u>; via email at <u>pablo.zuanic@zuanic@zuanic@gruanicgroup.com</u>; or via X @4200dysseus.*



Disclosures and Disclaimers

About the firm: Zuanic & Associates is a domestic limited liability company (LLC) registered in the state of New Jersey. The company's registered address is Five Greentree Centre, 525 Route 73, N Suite 104, Marlton, New Jersey 08053, USA. Pablo Zuanic is the registered agent. The firm publishes equity research on selected stocks in the cannabis and psychedelics sector, as well as thematic macro industry notes. The firm also provides consulting and advisory services. Potential conflicts of interest are duly reflected in the respective specific company reports.

Analyst Certification: The publishing analyst, whose name appears on the front page of this report, certifies that the views expressed in this independent research report accurately reflects his personal views about the subject securities or issuers discussed in this report. His opinions and estimates are based on his best judgement at the time of publication and are subject to change without notice. As per the company's policy, the author of this report does not own shares in any company he covers.

Other: This report is for use by professional and or institutional investors only, and it is deemed impersonal investment advice, published on a bona fide and regular basis. This report is for informational purposes only and is based on publicly available data believed to be reliable, but no representation is made whether such data are accurate or complete. As such, this report should not be regarded by its recipients as a substitute for obtaining independent investment advice and/or exercise of their own judgement. When making an investment decision this information should be viewed as just one factor in the investment decision process. Neither the publishing analyst, nor any of the company's officers and directors, accept any liability for any loss or damage arising out of the use of all or any part of the analyst's research.

Risks: The financial instruments mentioned in this report may not be suitable for all investors and investors must make their own investment decisions based on their specific investment objectives. Past performance should not be taken as an indication or guarantee of future performance. The price, value of and income from, any of the financial instruments featured in this report can rise as well as fall and be affected by changes in political, financial, and economic factors. If a financial instrument is denominated in a currency other than the investor's currency, a change in exchange rates may adversely affect the price or value of, or income derived from, the financial instrument, and such investors effectively assume currency risk.

Disclosure: Zuanic & Associates offers advisory and research services, and it also organizes investor events and conferences. The firm is often engaged by various operators in the cannabis industry (both plant touching companies and those providing services, private and public, in North America and overseas) on an ongoing or ad hoc basis. The company discussed in this report is a paying customer of the services provided by the firm.

Copyright: No part of this publication may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written permission of the author.